Make the most of what you’ve got: Vδ1+ γδ T cells
October 30, 2019
In order to effectively utilize immunotherapy against solid tumors, it is important to understand the underlying immune landscape of both tumors and the healthy tissues they grow in. To expand the understanding of the immune landscape in breast cancer, Wu and Kyle-Cezar et al. analyzed healthy and malignant breast samples from prophylactic and...
Antibodies come after TNFR2 to eradicate tumors
October 23, 2019
Searching for new cancer immunotherapies that are effective and well tolerated, Tam, Fulton, and Sampson et al. explored targeting tumor necrosis factor receptor 2 (TNFR2), which is mostly expressed on immune cells, including Tregs and activated T cells. In a paper recently published in Science Translational Medicine, the researchers generated and characterized anti-murine...
Effector or Exhausted: TCF-1 Seals T cell Fate
October 16, 2019
CD8+ T cell exhaustion plays a major role in chronic immune responses to both infection and cancer and is a major target of immunotherapy. To understand how and when exhaustion programs are initiated, Chen and Ji et al. analyzed gene expression data and transcription factor activity to define a binary fate decision early...
Anti-CTLA-4 relies on RIG-I for tumor control
October 9, 2019
Aiming to improve the consistency of response to checkpoint inhibitors, Heidegger and Wintges et al. explored how the signaling of RIG-I – a cytosolic sensor that detects double-stranded RNA during bacterial or viral infection – contributes to IFN-I production within the tumor microenvironment, and how it affects the antitumor immunity mediated by immune...
CICON19 - 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
October 2, 2019
Last week, the ACIR team attended the Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference in Paris, France. This week’s extensive special feature covers select talks from the conference, which are organized by the topics below. Targeting the PD-1 axis Vaccination approachesCARs targeting solid tumors or the tumor stromaTumor and the microenvironmentMicrobiota-immune interactionsBiology of innate...